← Product Code [DXZ](/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/DXZ) · K963611 # VASCUTEK CARDIOVASCULAR FABRIC: VASCUTEK GELSEAL PATCH,VASCUTEK GELSOFT PATCH,VASCUTEK THIN WALL CAROTID PATCH (K963611) _Vascutek, Ltd. · DXZ · Nov 21, 1996 · Cardiovascular · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/DXZ/K963611 ## Device Facts - **Applicant:** Vascutek, Ltd. - **Product Code:** [DXZ](/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/DXZ.md) - **Decision Date:** Nov 21, 1996 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 870.3470 - **Device Class:** Class 2 - **Review Panel:** Cardiovascular - **Attributes:** Therapeutic ## Indications for Use Vascutek Cardiovascular Fabric is indicated for vascular patch grafting and for intracardiac patching. The Thin Wall Carotid Patch is, in addition, indicated for patch closure after endarterectomy, particularly of the carotid arteries. ## Device Story Vascutek Cardiovascular Fabric consists of gelatin-sealed, knitted polyester patches (Gelseal, Gelsoft, Thin Wall Carotid). Gelatin sealant (bovine bone-derived, USP standard) eliminates need for preclotting during surgery, even in anticoagulated patients. Patches are implanted by surgeons during vascular or intracardiac procedures to repair or close tissue. Device provides structural support and sealing at surgical site. Benefits include reduced preparation time and improved hemostasis. ## Clinical Evidence Bench testing only. In-vitro performance testing compared subject patches to predicate (Meadox Hemashield) regarding burst strength, suture retention, tensile strength, and water porosity. Previously accepted animal testing cited for in-vivo performance of gelatin-sealed polyester material. ## Technological Characteristics Knitted polyester fabric impregnated with absorbable bovine bone-derived gelatin (USP). Porosity: 1460, 2118, and 3515 ml/min/cm². Sterilization: Ethylene Oxide. Shelf-life: 4 years. ## Regulatory Identification An intracardiac patch or pledget made of polypropylene, polyethylene terephthalate, or polytetrafluoroethylene is a fabric device placed in the heart that is used to repair septal defects, for patch grafting, to repair tissue, and to buttress sutures. ## Predicate Devices - Meadox Hemashield® Microvel® Double Velour Fabric ([K931386](/device/K931386.md)) ## Reference Devices - Vascutek Gelseal™ Vascular Graft (PMA [P890045](/device/P890045.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 10(6) SUMMARY VASCUTEK CARDIOVASCULAR FABRIC NOV 21 1996 K963611 The Vascutek Cardiovascular Fabric product line consists of a non-crimped Gelseal™ patch, Gelsoft™ patch, and a Thin Wall Carotid patch. Each patch product line is gelatin-sealed, knitted polyester, with a base fabric porosity of 1460 ml/min/cm², 2118 ml/min/cm² and 3515 ml/min/cm² respectively, and are available in various square or rectangular sizes. The polyester fabrics have been impregnated with an absorbable mammalian gelatin which seals the prostheses in the same manner as the fibrin deposited in traditional preclotting procedures. The gelatin sealant obviates the need for preclotting prior to implantation. The gelatin is of United States Pharmacopeia (USP) standard and is derived from bovine bone. The result is a family of cardiovascular patches that do not require preclotting even when patients have been anticoagulated or when bleeding is a prime concern. The gelatin has been shown to be safe and effective through the approval of the Vascutek Gelseal™ Vascular Graft, PMA# P890045 on January 11, 1993. Vascutek Cardiovascular Fabric is indicated for vascular patch grafting and for intracardiac patching. The Thin Wall Carotid Patch is, in addition, indicated for patch closure after endarterectomy, particularly of the carotid arteries. Vascutek Cardiovascular Fabric is manufactured from materials that have an extensive history of use in cardiovascular and other medical applications. This polyester material and gelatin sealant have been thoroughly tested and characterized with regard to biocompatibility and suitability for their intended use. Vascutek Cardiovascular Fabric is supplied sterile. The method of sterilization used is Ethylene Oxide. A shelf-life of 4 years has been established. Comprehensive in-vitro performance testing has been performed on Vascutek Cardiovascular Fabric. In-vitro performance testing performed on the Vascutek Gelseal™, Gelsoft™, and Thin Wall Carotid patches and the Meadox Hemashield Microvel Double Velour Fabric, which included burst strength, suture retention, tensile strength and water porosity, provides evidence that Vascutek Cardiovascular Fabric is substantially equivalent to the predicate fabric. Previously accepted animal testing has demonstrated acceptable in-vivo performance for the Vascutek Cardiovascular Fabric gelatin-sealed polyester material. CarboMedics considers Vascutek Cardiovascular Fabric safe, effective and substantially equivalent in intended use, material (polyester and sealant), and function to the Meadox Hemashield® Microvel® Double Velour Fabric which received marketing clearance on May 27, 1993 under 510(k) K931386. Common name of the device: Cardiovascular Patch Trade name of Proprietary name: Vascutek Cardiovascular Fabric: Vascutek Gelseal™ Patch Vascutek Gelsoft™ Patch Vascutek Thin Wall Carotid Patch Submitter and contact person: Teena M. Augostino, Manager, Regulatory Affairs 1300 E. Anderson Lane, Austin, TX 78752 Phone: (512) 435-3225 Fax: (512) 435-3350 Submission Submitted on: September 6, 1996 PH: (512) 435-3200 FAX (512) 435-3350 WATS (800) 648-1579 (US AND CANADA) --- **Source:** [https://fda.innolitics.com/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/DXZ/K963611](https://fda.innolitics.com/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/DXZ/K963611) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com